This is the Oregon Health Plan fee-for-service Preferred Drug List and
drug prior authorization (PA) searchable database.
All active and available drugs reported by First DataBank are included if they provide a federal rebate or are preferred.
Drugs are assigned to a PDL class if it has been reviewed by the
Oregon Pharmacy and Therapeutics Committee (P&T)
for comparative effectiveness and safety. All other drugs are classified by default to the
First DataBank Standard Therapeutic Class.
Drugs of higher effectiveness and/or safety or that are similar with lower cost are listed as preferred (Y).
Drugs of lower effectiveness and /or safety or that are similar with higher cost are listed as non-preferred
(N or V). Null (i.e. blank) indicates the class or specific drug has not been reviewed for PDL placement.
Non-preferred drugs listed as N require a PA for pharmacy payment.
New drugs approved by the FDA exclusively for indications that are not funded by the Oregon Health Plan are subject to the
Drugs for Non-funded Conditions criteria and all drugs in PDL
classes are subject to clinical PA criteria when applicable. New drugs that are not subject to current clinical criteria and cost more than $5,000 per claim or $5,000 per month
will be subject to the New Drug Policy until reviewed by the P&T Committee.
For instructions on requesting a PA, see the Oregon Medicaid PA Criteria
(you will need to scroll down to the PA section).
Non-preferred drugs listed as V (voluntary) do not require PA.
This page lists each drug class with links to the P&T meeting minutes where the class or drugs within the class were discussed. Further information
on specific drugs can be found on the individual class page (click on the class name to be taken to its page). Alternatively you can search for
individual drugs by brand or generic name.
Each individual drug class page lists any supporting documents presented at P&T for reference and lists the PDL status (Y, N, V or null) of each
drug in the class. PA or QL (quantity limit) indicates the drug requires prior authorization for safety considerations or to promote appropriate
step-therapy and links to the current approval criteria.
Drug Search